AllianceBernstein
RVMD icon

AllianceBernstein’s Revolution Medicines RVMD Stock Holding History

AllianceBernstein’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.13M Sell
63,051
-592
-0.9% -$86.5K ﹤0.01% 1425
2026
Q1 		$5.07M Sell
63,643
-2,880
-4% -$291K ﹤0.01% 1539
2025
Q4 		$5.3M Buy
66,523
+4,392
+7% +$288K ﹤0.01% 1514
2025
Q3 		$2.9M Buy
62,131
+2,125
+4% +$83.2K ﹤0.01% 1793
2025
Q2 		$2.21M Sell
60,006
-134,072
-69% -$5.15M ﹤0.01% 1887
2025
Q1 		$6.86M Sell
194,078
-40,851
-17% -$1.66M ﹤0.01% 1327
2024
Q4 		$10.3M Sell
234,929
-15,932
-6% -$804K ﹤0.01% 1178
2024
Q3 		$11.4M Sell
250,861
-68,757
-22% -$2.99M ﹤0.01% 1117
2024
Q2 		$12.4M Sell
319,618
-3,746
-1% -$140K ﹤0.01% 1058
2024
Q1 		$10.4M Buy
323,364
+3,119
+1% +$92.4K ﹤0.01% 1142
2023
Q4 		$9.18M Buy
320,245
+64,202
+25% +$1.54M ﹤0.01% 1211
2023
Q3 		$7.09M Sell
256,043
-72,595
-22% -$2.15M ﹤0.01% 1267
2023
Q2 		$8.79M Sell
328,638
-47,812
-13% -$1.17M ﹤0.01% 1189
2023
Q1 		$8.15M Buy
376,450
+160,050
+74% +$3.94M ﹤0.01% 1179
2022
Q4 		$5.15M Sell
216,400
-37,862
-15% -$805K ﹤0.01% 1410
2022
Q3 		$5.01M Buy
254,262
+56,965
+29% +$1.25M ﹤0.01% 1402
2022
Q2 		$3.85M Sell
197,297
-28,371
-13% -$552K ﹤0.01% 1578
2022
Q1 		$5.76M Buy
225,668
+120,086
+114% +$2.61M ﹤0.01% 1513
2021
Q4 		$2.66M Buy
105,582
+19,482
+23% +$549K ﹤0.01% 1968
2021
Q3 		$2.37M Buy
86,100
+20,000
+30% +$582K ﹤0.01% 2066
2021
Q2 		$2.1M Buy
66,100
+8,900
+16% +$311K ﹤0.01% 2161
2021
Q1 		$2.62M Buy
57,200
+900
+2% +$40.4K ﹤0.01% 1927
2020
Q4 		$2.23M Buy
56,300
+400
+0.7% +$15.8K ﹤0.01% 1911
2020
Q3 		$1.95M Buy
55,900
+33,773
+153% +$935K ﹤0.01% 1862
2020
Q2 		$699K Buy
+22,127
New +$696K ﹤0.01% 2401

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

AllianceBernstein's RVMD Position: Q2 2026 in Review

AllianceBernstein reduced its Revolution Medicines (RVMD) stake by 0.93% in Q2 2026, selling an estimated $86.5K and leaving 63,051 shares worth $6.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

AllianceBernstein first reported a position in RVMD in Q2 2020 and has held it in 25 quarters since. The position peaked at $12.4M in Q2 2024. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • AllianceBernstein held 63,051 shares of Revolution Medicines worth $6.13M as of Q2 2026.
  • AllianceBernstein sold 592 Revolution Medicines shares in Q2 2026, an estimated $86.5K.
  • Revolution Medicines made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1425 holding.
  • AllianceBernstein first reported a position in Revolution Medicines in Q2 2020 and has held it in 25 quarters since.
  • AllianceBernstein's Revolution Medicines position peaked at $12.4M in Q2 2024.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.